Pacira BioSciences, Inc.
$ 23.75
-1.29%
14 Apr - close price
- Market Cap 1,035,092,000 USD
- Current Price $ 23.75
- High / Low $ 24.36 / 23.69
- Stock P/E 150.38
- Book Value 16.86
- EPS 0.16
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE 0.01 %
- 52 Week High 27.64
- 52 Week Low 18.80
About
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare professionals and their patients in the United States. The company is headquartered in Parsippany, New Jersey.
Analyst Target Price
$28.71
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-11-06 | 2025-08-05 | 2025-05-05 | 2025-02-26 | 2024-11-06 | 2024-07-30 | 2024-05-07 | 2024-02-29 | 2023-11-02 | 2023-08-02 | 2023-05-03 |
| Reported EPS | 0.57 | 0.7 | -0.11 | 0.62 | 0.91 | 0.79 | 0.89 | 0.62 | 0.89 | 0.72 | 0.78 | 0.53 |
| Estimated EPS | 0.9017 | 0.65 | 0.72 | 0.5971 | 0.8303 | 0.7 | 0.7 | 0.62 | 0.88 | 0.78 | 0.76 | 0.62 |
| Surprise | -0.3317 | 0.05 | -0.83 | 0.0229 | 0.0797 | 0.09 | 0.19 | 0 | 0.01 | -0.06 | 0.02 | -0.09 |
| Surprise Percentage | -36.7861% | 7.6923% | -115.2778% | 3.8352% | 9.5989% | 12.8571% | 27.1429% | 0% | 1.1364% | -7.6923% | 2.6316% | -14.5161% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.33 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PCRX
2026-04-13 19:10:33
Pacira BioSciences, Inc. presented real-world data at the AMCP Annual 2026 Meeting, highlighting that its drug EXPAREL is associated with lower or comparable total healthcare costs and reduced opioid use in outpatient total hip and knee arthroplasty procedures. The analyses indicated cost savings for Total Hip Arthroplasty (THA) patients, particularly those with lower back pain, and comparable or lower costs for Total Knee Arthroplasty (TKA), especially in teaching hospitals. A three-year budget impact analysis further projected significant cost differences in favor of EXPAREL in outpatient settings.
2026-04-13 12:09:25
Pacira BioSciences presented real-world data at the AMCP Annual 2026 Meeting showing that its non-opioid pain therapy, EXPAREL, is associated with lower total healthcare costs and reduced opioid use in outpatient total hip and knee arthroplasty procedures. Studies indicated cost savings over several months post-surgery, especially for patients with lower back pain or in teaching hospitals. The findings reinforce EXPAREL's value in pain management by benefiting patients, providers, and payers through cost reduction and opioid stewardship.
2026-04-13 12:09:25
Pacira (NASDAQ: PCRX) presented real-world data at AMCP 2026 showing that EXPAREL (liposomal bupivacaine) was associated with lower or comparable total healthcare costs and reduced opioid use in select cohorts undergoing outpatient total hip (THA) and total knee arthroplasty (TKA). The studies indicated significant cost reductions for THA patients, especially those with low back pain, and comparable or lower costs for TKA, particularly in teaching hospitals, despite higher pharmacy acquisition costs for EXPAREL. The findings reinforce EXPAREL's economic value and role in non-opioid pain management.
2026-04-09 17:39:20
Dimensional Fund Advisors has reported beneficial ownership of 2,060,597 shares of Pacira BioSciences (PCRX) common stock, representing 5.1% of the class as of March 31, 2026. This disclosure was made via a Schedule 13G SEC filing, indicating a passive investment by the firm on behalf of various funds it advises. While Dimensional exercises significant voting and dispositive power, it disclaims direct beneficial ownership, stating the shares are held by its client funds.
2026-04-09 06:39:00
Pacira BioSciences announced its participation in an analyst-led fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026, at 9:30 AM ET. The company also disclosed the granting of inducement awards to new employees on April 2, 2026, under its Amended and Restated 2014 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). These awards consist of stock options and restricted stock units, designed to attract and retain talent.
2026-04-09 05:39:20
Pacira Biosciences Inc (PCRX) currently has a "Strong Buy" technical consensus from Intellectia.AI, based on 11 buy signals and 3 sell signals across 14 technical indicators. The stock's MACD indicates a "Strong Buy" and it is trading above its 200-day simple moving average, suggesting a long-term bullish trend. Key support is at $21.925 and resistance at $23.995.
